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Abstract Low blood levels of long chain omega-3
polyunsaturated fatty acids (LC n-3 PUFA) have been
reported to be associated with increased risk for cardio-
vascular disease (CVD) deaths. Systematic studies mea-
suring LC n-3 PUFA blood levels (pre and post-treatment)
in defined subjects, and monitoring the correction of
nutritional deficiency with a pure LC n-3 PUFA formula-
tion in sufficient doses, while monitoring CVD risk factors
are lacking. We tested the efficacy of a novel LC n-3 PUFA
Medical Food formulation (VASCAZEN, [ 90 % pure
with a 6:1 eicosapentaenoic acid-(EPA):docosahexaenoic
acid-(DHA) ratio; 6:1-OM3), to correct such deficiency
and determine the concomitant effects on lipid profiles. Of
655 subjects screened, 89 % were LC n-3 PUFA deficient
(Omega-Score, (OS) = blood EPA ? DHA ? Docosa-
pentaenoic acid \ 6.1 %). From these, a study was con-
ducted on 110 ambulatory cardiovascular subjects.
Placebo: corn oil. Primary endpoint: change in OS. Sec-
ondary endpoint: changes in blood lipid profiles. At
8 weeks of treatment with 6:1-OM3 (4 g/day), placebo-
adjusted median OS levels (n = 56) significantly improved
(132 %, P \ 0.0001) with a decrease in AA (arachidonic
acid): EPA ratio (82 %, P \ 0.0001). In hypertriglyceri-
demic subjects (TG 2.26–5.65 mmol/L), HDL-C improved
(9 %, P = 0.0069), TG-reduced (48 %, P \ 0.0001), and
VLDL-C reduced (30 %, P = 0.0023), without signifi-
cantly affecting LDL-C levels. This study confirms that LC
n-3 PUFA deficiency is prevalent in the US population, and
its correction with 6:1-OM3 in CVD subjects improves
lipid profiles. The purity, EPA:DHA ratio and dose are
determinant factors for optimal efficacy of a formulation in
reducing CVD risk factors.
Keywords Nutrition  Omega-3 (n-3) polyunsaturated
fatty acids  Omega-3 deficiency  Lipids and lipoproteins,
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Introduction
The cardiovascular health benefits of a diet rich in fish has
been known for decades and such benefits have been
attributed to the presence of LC n-3 PUFA found in fish [1–
4]. The typical Western Diet is relatively deficient in LC
n-3 PUFA but enriched in saturated fat and n-6 PUFA [5],
leading to chronic LC n-3 PUFA deficiency in the US
population. About 70 % of the US population, assessed on
the basis of dietary intake, is deficient in LC n-3 PUFA
blood levels [6]. Such deficiency can be determined
through the measurement of EPA ? DHA ? DPA (doco-
sapentaenoic acid) levels in blood (Omega-ScoreTM, OS)
or of EPA ? DHA levels in red blood cells (Omega-3
Index, OI) [7, 8]. Although cut-off levels for OS or OI have
yet to be defined, LC n-3 PUFA dietary deficiency or
insufficiency has been identified as a risk factor attributable
to 84,000 all cause deaths per year in the US [9]. In a
prospective trial, through analyses of blood samples from
the Physicians’ Health Study, the lowest quartile of LC n-3
PUFA has been correlated to about 81 % increased risk of
sudden cardiac death among men without prior evidence of
CVD [10]. Based upon ‘‘risk quartiles’’ of OS levels, the
authors concluded that an OS[6.1 % is strongly associated
with a reduced risk for sudden cardiac death. Similar
findings were reported earlier where a strong inverse
relationship between OI and primary cardiac arrest was
described [11]. More recently, quintiles of individual EPA,
DHA,and DPA levels have been shown to be associated
with lower cause-specific CVD mortality and their com-
bined levels were associated with a 35 % lower risk [12].
Furthermore, the clinical utility of the OI has been sug-
gested not only as a biomarker of intake but also as an
important risk factor for CVD and target for therapy [8,
13].
Despite the known beneficial effects of LC n-3 PUFA, a
number of meta-analyses of randomized controlled trials
(RCT) have generated controversy for their use as a pre-
ventive treatment option for CVD subjects [14–17]. Some
of the studies included had study design deficiencies that
may have contributed to outcomes. The treatments
employed were often either of low purity with varying
ratios of EPA and DHA, and/or doses were suboptimal.
Importantly, many studies that employed high purity sup-
plements did not measure OS or OI levels either at pre- or
at post-treatment [18–20]. In other studies, either baseline
EPA levels (2.9 % of the total fatty acids) were high [19],
or fish consumption increased significantly during the study
[21] that may have undermined the beneficial effects of the
treatment. Others have often included patients on con-
comitant medications (though unavoidable), which can
possibly affect the trial outcomes [22–24]. For example,
amiodarone, an antiarrhythmic agent, has been shown to be
a potent phospholipase inhibitor [25], an enzyme needed
for the fatty acid turnover (acylation/de-acylation cycle) in
cell membranes. In addition, the choice of placebo
employed could also affect placebo-corrected results [26].
The importance of these limitations and emphasis on
patient selection, individual patient data meta-analysis,
insufficient dose,and purity of supplement have been
emphasized in recent reviews [17, 27, 28]. With the
exception of von Schacky and Harris [7, 8, 29, 30] who
proposed the OI as an important marker of CVD risk,
investigations of the prevalence of LC n-3 PUFA nutri-
tional deficiency and its correction, with health-promoting
effects that correlate with increased EPA and DHA intake
are lacking.
The primary objective of the present RCT was to
investigate the efficacy of a highly pure and a novel 6:1-
OM3 formulation to correct LC n-3 PUFA deficiency and
improve lipid profiles in ambulatory CVD subjects. To
accommodate suggestions proposed in previous reviews
[17, 27, 28], the present study (a) selected the subjects with
LC n-3 PUFA insufficiency (OS \ 6.1 %) with normal and
high TG (1.02–5.65 mmol/L, representing 90–500 mg/dL)
levels, (b) employed high doses of EPA ? DHA (3.2 g/d)
with [90 % purity in a novel 6:1 EPA:DHA formulation,
which has been shown to produce maximum and sustained
vasodilatory effects in isolated perfused porcine coronary
artery rings than other known EPA alone or EPA:DHA
(1.2:1) preparations [31] and finally (c) measured both pre-
and post-treatment OS and OI levels to correlate changes
with the trial objectives. Preliminary work of this study has
been presented [32].
Experimental design and methods
This study entitled ‘‘A Placebo-ContRollEd Study of
VASCAZEN in Subjects with DEficient Blood LC n-3
Fatty Acid Levels’’, the VASCAZEN-REVEAL Trial,
was an external contract research organization (CRO)-
facilitated study managed by Nutrasource Diagnostics Inc.,
Guelph, Ontario, Canada, and conducted at two centers in
the United States. The CRO was responsible for all trial
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operations, including research ethics board communica-
tions and protocol approvals, staff training, site visits, data
management, and they followed current Good Clinical
Practice, the Declaration of Helsinki guidelines, and
research ethics board guidelines and requirements. The
study protocol was approved by the Canadian SHIELD
Ethics Review Board. Pivotal Therapeutics Inc. (Wood-
bridge, Ontario, Canada) sponsored the study.
This 8-week study was a multicenter, randomized,
double-blinded, placebo-controlled study that investigated
LC n-3 PUFA nutritional deficiency and its correction with
4 g/day of corn oil or 6:1-OM3 formulations (Supplied by
Pivotal Therapeutics Inc). Ambulatory cardiovascular
subjects were questioned and screened for their eligibility
into the trial. Male and female study subjects C18 years of
age, with one or more risk factor for CVD, were deemed
eligible for study enrollment if their fasting whole blood
OS levels were\6.1 % by weight of total blood fatty acid
levels, and their serum TG was between 1.02 and
5.65 mmol/L. Subjects were excluded from the study if
they refused to provide informed consent, had a known
allergy to fish, were premenopausal women, were currently
taking hormone replacement therapy (HR), lipid-altering
medication or LC n- PUFA supplements, had a history of
alcohol abuse, were medically ill, had a history of ven-
tricular arrhythmia, bleeding or clotting disorder, liver or
kidney disease, autoimmune disorder or suppressed
immune systems, myopathy or rhabdomyolysis, seizure
disorder, or had an implantable cardioverter defibrillator.
Subjects on a stable statin medication for a minimum of
three months were eligible to enroll.
All eligible subjects were randomized using a list gen-
erated by the CRO (random assignment of ‘‘Treatment A’’,
or ‘‘Treatment B’’), to receive four 1 g capsules per day of
either corn oil (placebo) or 6:1-OM3 (providing a minimum
of 2.72 g/day of EPA and 440 mg/day of DHA). Corn oil
was almost completely devoid of LC n-3 PUFA and mostly
consisted of n-6 & n-9 fatty acids (linoleic 59 %; oleic
25 %; palmitic 11 %; stearic 2 %), while 6:1-OM3 con-
tained over 94 % LC n-3 PUFA and less than 5 % n-6 fatty
acids. Both treatment capsules were indistinguishable from
one another, and packaged by a third party in white identical
boxes labeled ‘‘Treatment A’’ or ‘‘Treatment B.’’ Subjects
were stratified by their baseline TG levels into two Cohorts.
Cohort 1 included subjects with normal to marginally high
TG levels (1.02–2.25 mmol/L representing 90–199 mg/dL)
and Cohort 2 included subjects with hypertriglyceridemia
(2.26–5.65 mmol/L representing TG 200–500 mg/dL).
Randomization was on a 1:1 basis to ensure approximately
equal numbers of subjects in each of the two treatment
arms. All investigators, the CRO, and the study sponsor,
remained blinded to the treatment regimen during the
study’s progress.
The primary end point of the study was to determine the
efficacy of the 6:1-OM3 treatment to correct LC n-3 PUFA
deficiency, by measuring the placebo-adjusted change in
blood OS and OI levels post-treatment. Secondary outcome
measures included changes in serum levels of TG, VLDL-
C, IDL-C, LDL-C, HDL-C, apo-A, apo-B, total cholesterol
(TC), high sensitivity C-reactive protein (hs-CRP), ara-
chidonic acid (AA):EPA ratio, n-6:n-3 ratio, and fasting
blood glucose from the study baseline to the study end
point after 8 weeks of treatment.
Treatment schedule and subject evaluation
Enrolled subjects provided the baseline 12-hour fasting
blood specimens for analyses and completed the health
assessment forms. In addition, subject weight, body mass
index (BMI), waist and hip circumference and blood
pressure were measured and recorded in case report forms.
Subsequent to the collection of baseline blood specimens,
enrolled subjects were stratified as Cohort 1 or Cohort 2
based upon their fasting TG levels obtained at the screen-
ing evaluation. Subjects in each Cohort were provided with
4 capsule/day doses of either Treatment A or B for
8 weeks. All subjects provided 10–12-hour fasting blood
specimens by venipuncture at week 0 (baseline) and after 4
and 8 weeks of treatment. The samples were sent for
analyses of the primary and secondary measures, as
described below. In addition, health assessments (weight,
BMI, blood pressure), capsule compliance evaluation, and
adverse events reporting were measured, and reported at
each subsequent clinic visit. An emergency number was
provided to each study participant for reporting any serious
adverse reaction during the entire study period.
Sample analysis
Analyses of total blood fatty acids levels, including OS, OI,
AA:EPA ratio, n-6:n-3 ratio and fasting blood glucose were
performed at a central laboratory, (University Health Net-
work, Specialty Laboratory, Toronto, Ontario, Canada),
accredited by the College of American Pathologists’ Lab-
oratory Accreditation Program. The fatty acid composi-
tions of whole blood were determined on 200 ll of sample
after lipid extraction by a modification of the method of
Bligh and Dyer [33]. The total lipid fraction was then
methylated with 12 % (w/w) boron trifluoride in methanol
by incubation at 90 C for 25 min to produce fatty acid
methyl-esters (FAME). After cooling, the FAME were
extracted with hexanes, washed with water, dried under
nitrogen and dissolved in hexanes. The fatty acid compo-
sition was then determined by GLC performed on a 100 m
Varian SelectTM FAME CP7420 capillary column
(0.25 mm i.d.), using an Agilent Technologies 6890 N
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series gas chromatograph equipped with a split/splitless
mode injector, and a flame ionization detector. The injector
and detector were maintained at 280 and 300 C,respec-
tively, and samples were analyzed by multilevel tempera-
ture programing in the range of 90–265 C with ultra high
purity grade helium as the carrier gas. The percent com-
position of fatty acids was calculated from the individual
peak areas using appropriate standards. The procedure was
routinely validated by proficiency testing using GC/MS.
The OS levels were calculated by adding the individual
EPA, DPA, and DHA levels. The OI was determined as
previously described [13].
Analyses of all other serum analytes, including TG,
VLDL-C, IDL-C, LDL-C, HDL-C, apo-A, and apo-B, hs-
CRP were performed at Atherotech Diagnostics Lab (Bir-
mingham, Alabama, USA), as described earlier [34].
Power and sample size
Earlier randomized placebo-controlled studies have indi-
cated that the administration of EPA or DHA therapy over
a 6 to 7 week time period can result in an increase in blood
LC n-3 PUFA levels of at least 47 % and a decrease in
blood TG levels of 18–21 % [35, 36]. Assuming a mean
baseline blood OS level of at least 3 % and a change in
standard deviation of 1.5 % within a given study stratum
[37], a sample size of 40 subjects per study stratum (i.e. 20
subjects assigned to 6:1-OM3 therapy, and 20 subjects
assigned to placebo) would result in a minimum power of
90 % to detect an increase in blood OS levels of at least
60 % in subjects within the 6:1-OM3 study arm relative to
subjects within the placebo arm, at a significance level of
alpha = 0.05 [37]. Assuming a mean baseline blood TG
levels of at least 1.58 mmol/L and a change standard
deviation of 0.40 mmol/L within a given study stratum, the
proposed sample size of 40 subjects per study stratum (i.e.
20 subjects assigned to 6:1-OM3 therapy, and 20 subjects
assigned to placebo) would result in a minimum power of
95 % to detect a relative decrease in blood TG levels of at
least 30 % in subjects within the 6:1-OM3 study arm rel-
ative to subjects within the placebo arm, at a significance
level of alpha = 0.05.
Data analyses
At the conclusion of the study, the Clinical Trial Review
Committee assessed the CRF for compliance with the
protocol and subjects who ingested a minimum of 80 % of
the assigned capsules were locked in. The tabulated data
were then un-blinded and analyses performed on the ‘‘per
protocol’’ subset of study. The median change and inter-
quartile range in blood OS and OI levels over the 8-week
period, as well as all secondary outcome measures was
computed for each study subject and organized by sub-
populations based on treatment group, and cohorts. Percent
changes from baseline to week 8 were calculated for each
treatment group (placebo and 6:1-OM3) and placebo-
adjusted median percent changes were then calculated. A
two-tailed t test (unpaired) was performed using GraphPad
Prism version 6.0 for Macintosh (GraphPad Software) to
illustrate placebo-adjusted changes and significance was
defined as a P value B0.05.
Safety evaluation
The qualified principal investigators at each site evaluated
patient health while remained blinded to the study treat-
ment regiment. All adverse events, defined as ‘‘treatment-
emergent’’ (TEAE), which occurred during the study per-
iod, were evaluated and classified as related or unrelated to
treatment by the principal investigator. Each TEAE was
recorded in an individual subject’s case report form at each
clinic visit, through patient health evaluations, including a
questionnaire, physical examination, clinical laboratory
test evaluations, weight, and BMI. Reports were compiled,
and categorized based upon grade, severity, and relation-
ship to study treatment. The Clinical Trial Review Com-
mittee reviewed the subjects’ case report forms, and agreed
with the principal investigator’s assignments.
Results
Study description and demographic characteristics
of the enrolled subjects
The study protocol outline is shown in Fig. 1. Of the 655
screened, 509 subjects were ineligible for study enrollment
as per inclusion/exclusion criteria in the methods section.
The remaining 146 subjects were stratified into two
Cohorts and were randomized, blinded and treated with
either corn oil (A) or 6:1-OM3 (B). Thirty-six subjects
were either lost to follow-up or the compliance with the
treatment was less than 80 %. The OS data from the 655
screened subjects showed LC n-3 PUFA nutritional defi-
ciency was prevalent in general US population, with 89 %
of subjects falling below 6.1 % OS (median OS 4.48 %;
range 1.84–5.89 %).
The baseline characteristics of the enrolled and ran-
domized study population (Table 1) were comparable
within Cohorts, and across treatment groups with approx-
imately equal numbers of males and females enrolled. The
median baseline LC n-3 PUFA level (measured as OS or
OI) or mean serum TG levels were comparable among two
Cohorts and treatment groups. The mean BMI was [30
(obese) for all groups and Cohorts. Statin use was also
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n = 9                              n = 13
Lost to Follow Up
n = 8                                     n = 6
Fig. 1 Study design and patient disposition
Table 1 Baseline
characteristics of the study
participants
a Results are mean ± SD of
(n) determinations
b Numbers in parentheses are
% of the total in each group
Cohort 1 Cohort 2
Placebo 6:1-OM3 Placebo 6:1-OM3
(n = 32) (n = 36) (n = 22) (n = 20)
Age (years) 56.0 ± 16.6 53.4 ± 13.9 50.5 ± 11.7 53.5 ± 12.1
Male/Female (numbers) 15/17 21/15 11/11 12/8
Median Omega-Score (interquartile range) 3.38 (0.97) 3.64 (0.94) 3.36 (1.10) 3.15 (0.88)
Baseline parametersa
BMI (kg/m2) 31.8 ± 7.0 30.8 ± 7.1 32.5 ± 4.3 33.3 ± 6.7
MAP (mmHg) 93.1 ± 8.5 91.4 ± 9.1 94.4 ± 6.9 94.6 ± 8.5
Risk factorsb
Diabetes 6 (18.8 %) 3 (8.3 %) 2 (9.1 %) 3 (15.0 %)
Hypertension 11 (34.4 %) 10 (27.8 %) 6 (27.3 %) 8 (40.0 %)
Patients on a statin 8 (25.0 %) 4 (11.1 %) 4 (18.2 %) 4 (20.0 %)
HDL \ 0.78–1.04 mmol/L (Male–Female) 19 (59.4 %) 26 (72.2 %) 17 (77.3 %) 13 (65.0 %)
Serum lipids (mmol/L)a
Total blood cholesterol 4.54 ± 0.82 4.86 ± 0.88 4.76 ± 0.77 5.30 ± 1.47
Total LDL-C 2.66 ± 0.67 3.09 ± 0.79 2.76 ± 0.69 3.19 ± 1.13
Total HDL-C 1.21 ± 0.33 1.08 ± 0.22 1.01 ± 0.22 1.01 ± 0.25
Triglycerides 1.58 ± 0.36 1.63 ± 0.41 3.14 ± 0.70 3.44 ± 1.03
Mol Cell Biochem (2014) 396:9–22 13
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similar, except for placebo group in Cohort 1, which had
twice as many subjects on this drug as in other groups.
Additional CVD risk indicators such as diabetes, hyper-
tension, and low HDL-C are approximately similarly
matched among Cohorts and treatment groups (Table 1).
Primary end point measure: correction of LC n-3 PUFA
deficiency
The data presented in Fig. 2 show median OS levels of all
6:1-OM3 study subjects (n = 56) and of subjects in each
Cohort group at baseline and after treatment for 8 weeks,
when superimposed on to a previously defined risk quar-
tiles Ref. [10]. Figure shows that regardless of baseline TG
status, the median baseline OS was similar, and treatment
with 6:1-OM3 effectively corrected LC n-3 PUFA defi-
ciency by raising the median OS significantly in combined
Cohorts (132 %, P \ 0.0001) or in Cohort 1 & 2 (132 % &
121 %, P \ 0.0001, respectively). The baseline median OS
levels and the extent of correction in two Cohorts appeared
to be dependent upon initial baseline TG levels (i.e., the
higher the baseline TG, the lower the OS and lesser the
correction with LC n-3 PUFA). The OS and OI indices
increased in a similar fashion after 8 weeks of treatment
(Table 2). As expected, both of these indices did not
change in the placebo group, indicating that the dietary
intake of the study participant were in compliance with the
study protocol and did not change during the course of the
trial.
The frequency distribution curve (Fig. 3a) shows that
the correction of LC n-3 PUFA deficiency was subject
dependent as a broader OS distribution was observed
following 6:1-OM3 treatment than was observed at
baseline. This is more evident in a scatter plot (Fig. 3b)
where 12 out of 56 subjects (21 %) were found to be
weak responders (solid line circle) as their mean OS
changed by only 50 % (OS 3.0–4.5 %) as compared to
132 % for the combined group (n = 56). Another 11 out
of 56 subjects (20 %) responded strongly (dotted line
circle) to treatment where the greatest increase of 183 %
(OS [ 10.2) in OS was observed. The weak responders
tend to be associated more with hypertriglyceridemic
subjects (n = 8, Cohort 2), than with normal to mar-
ginally high TG subjects (n = 4, Cohort 1) while the
strong responders belonged more to Cohort 1 (n = 8)
than to Cohort 2 (n = 3). The average responders
(n = 33), comprised 59 % of the treated subjects,
showed a 121 % increase in OS with the majority
(73 %) belonging to the normal to marginally high TG
group.
Very High Risk High Moderate Low Risk
Baseline 
Median OS 3.34%
8 weeks of treatment 132% 
Endpoint
Median OS 7.61%
Very High Risk High Moderate Low Risk
3.15%
8 weeks of treatment
6.78%
OS (% of total blood fatty acids)
Very High Risk High Moderate Low Risk
3.64%
8 weeks of treatment
7.83%









Fig. 2 Change in blood median OS (primary endpoint) following
8 weeks of treatment with 6:1-OM3. A Total 6:1-OM3 treated
(n = 56) in both Cohorts, B Cohort 1 (baseline TG 1.02–2.25 mmol/L,
n = 36), and C Cohort 2 (baseline TG 2.26–5.65 mmol/L, n = 20).
Percentage increases (box) represent a significant change
(P \ 0.0001) in placebo-adjusted median OS from baseline to week
8. Risk quartiles were adapted from previously published data [10].
For abbreviations, see text
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Secondary end point measures: effect of treatment
on lipid profile
Table 2 and Fig. 4 illustrate the effects of 6:1-OM3 treat-
ments on the secondary end points in both Cohorts. Cohort 2
subjects showed significant reduction in placebo-adjusted
median levels of TG (47.8 %, P = 0.0005), and of VLDL-
C (30.2 %, P = 0.0023), a significant increase in HDL-C
levels (9.1 %, P = 0.0069), without any significant change
in LDL-C (11.3 %, P = 0.1164) or in other secondary
endpoints, including BMI, blood pressure, hs-CRP, apoli-
poproteins, and glucose. Arachidonic acid to EPA ratio and
n-6:n-3 ratio significantly decreased (87.0 %, P \ 0.0001;
45.5 %, P \ 0.0001, respectively) in the 6:1-OM3 group as
compared to placebo (Fig. 5b). Unlike Cohort 2, study
subjects in Cohort 1 only showed a downward (-8.0 %),
but a non-significant trend (P = 0.1140) in TG levels upon
6:1-OM3 treatment (Table 2). Similarly, lipoprotein-asso-
ciated cholesterol in all fractions or other end points mea-
sures listed in table did not change significantly upon either
treatment with the exception of AA:EPA and n-6:n-3 ratios.
Both AA:EPA and n-6:n-3 ratios were reduced significantly
by 93.0 % (P \ 0.0001) and 48.6 % (P \ 0.0001),
respectively and this reduction was comparable to that of
Cohort 2 as described above (Table 2, Fig. 5b).
The time course of changes in OS and OI were similar,
reached a plateau after 4 weeks of treatment (Fig. 5A), and
did not change significantly thereafter. The differential
changes in individual LC n-3 PUFA are illustrated in Fig. 5C.
All three PUFA, regardless of Cohort designation signifi-
cantly changed after 4 weeks of treatment, reached a plateau
and increased very little thereafter. The relative increases were
very high for EPA (408 %), followed by DPA (75 %) and
DHA (47 %) at the study endpoint. As expected, these com-
ponents in the placebo group remained unchanged. The time
Fig. 3 Change in OS (primary
endpoint) at baseline and upon 8
weeks of treatment with 6:1-
OM3 (n = 56). A Frequency
distribution plot of panel B
subjects with a broad
distribution of OS due to weak
versus strong responders.
B Scatter plot of OS in 6:1-OM3
treated. Weak- and strong
responders are circled with solid
and dotted lines,
respectively and horizontal
lines at baseline and 8 week
represent median values
Fig. 4 Percent change from baseline to week 8 of placebo-corrected blood
lipid levels in Cohort 2 subjects (baseline TG 2.26–5.65 mmol/L). Analysis
was on the per protocol population. *9.05 % increase (P = 0.0069);
**30.20 % decrease (P = 0.0023); ***47.75 % decrease (P = 0.0005)
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course of changes in the AA:EPA and n-6:n-3 ratios were also
similar (Fig. 5B), and both of these inflammatory indices
decreased significantly (82 % and 51 % respectively, P \
0.0001) upon 8 weeks of 6:1-OM3 treatment.
Safety
No serious adverse events related to the study treatment
were observed (Table 3). The data shown includes TEAE
with an incidence of [3 % across treatment groups, irre-
spective of Cohorts. All TEAE observed were transient,
mild in nature and did not require any treatment.
Discussion
In this study, we investigated the efficacy of a novel 6:1-
OM3 formulation to correct LC n-3 PUFA nutritional
deficiency and determined concomitant improvement in
lipid profiles in subjects with one or more risk factors for
CVD. Due to the highly variable demographic (geograph-
ical, cultural) dietary intakes of US population it is difficult
to assign a ‘‘normal’’ blood level or assign cut-off value
that indicate nutritional LC n-3 PUFA deficiency or
insufficiency, as the words often used previously for other
fatty acids [38, 39] expressed as blood OS or OI numbers.
Harris et al. [13, 40] elegantly discussed the need for
establishing ‘‘dietary reference intakes’’ for EPA and DHA
Fig. 5 Time-course change in OS, OI, AA:EPA and n-6:n-3 ratios,
and in individual LC n-3 PUFA components (n = 56) in both Cohorts
upon 8 weeks of treatment with 6:1-OM3 and with placebo.
A Changes in OS and OI. B Changes in inflammatory indicators,
and C Changes in individual blood EPA, DPA, and DHA levels. All
changes were significant (P \ 0.0001) following 4 and 8 weeks of
treatment. For abbreviations, see text
Table 3 Safety profile (TEAE in [3 % of study subjects)*
Placebo 6:1-OM3 Total
n = 54 n = 56 n = 110
Fishy burp 0 (0.0 %) 3 (5.4 %) 3 (2.7 %)
Flatulation 0 (0.0 %) 2 (3.6 %) 2 (1.8 %)
Nausea 3 (5.6 %) 2 (3.6 %) 5 (4.5 %)
* Number (and percentage) of patients experiencing TEAE in each
group during the course of the study. TEAE: Treatment-emergent
adverse events
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and summarized the evidence for the proposed cut-off
points for the OI based upon data from earlier studies.
Earlier work by Albert et al. [10], showed an inverse
relationship between low OS quartile and the increased
incidence of sudden cardiac death. Mozaffarian et al. [12]
recently authenticated the inverse relationship among low
levels of individual or combined EPA, DHA, or DPA and
the increased incidence of total mortality associated with
CVD. Taken together, these studies shed some light on
target OS or OI levels that offer the greatest protection, as
described above. It was suggested that an OS of [6.1 %
[10, 12] or OI of[8.0 % [8, 11] reduce CVD-related risk to
the greatest extent, and these ‘‘target values’’ could be
considered as optimal for CVD patient health. Based upon
these studies, we chose to use an OS value of 6.1 % as a
cut-off number to select study subjects designated as LC
n-3 PUFA deficient. The data presented here show that
89 % of the 655 randomly selected screened subjects fell
well below the 6.1 % OS cut-off value discussed above.
The data confirm that the prevalence of LC n-3 PUFA
deficiency in the US population is alarmingly high, putting
subjects at greater risk for CVD complications and pre-
mature death, as was stipulated earlier [9]. Further, the
median blood OS value in our screened subjects (n = 655)
was 4.48 %, which is similar to the mean OS of 4.82 %
that was determined earlier in participants who died sud-
denly from cardiac causes without prior evidence of CVD
[10]. Thus the evaluation of LC n-3 PUFA status can be
used as a valuable tool to select study subjects for RCT
investigating the effects of LC n-3 PUFA supplementation,
to determine if an adequate dose is provided to subjects to
overcome LC n-3 PUFA deficiency, and to investigate its
effect on the study outcome. A shift of focus from LC n-3
PUFA nutritional ‘‘intake’’ to the measurement of LC n-3
PUFA ‘‘levels’’, at pre- and post-treatment should be a key
consideration for studies evaluating the effectiveness of LC
n-3 PUFA treatment.
In the present study, the median baseline OS of the
subjects (n = 56) was 3.34 %, lying in the highest risk
quartile (OS 2.12–4.32 %) for CVD death [10]. This LC
n-3 PUFA deficiency was effectively corrected raising OS
to 7.61 % (?132 %) within 8 weeks of treatment,
achieving levels that lie in the lowest risk quartile (OS
6.08–10.02 %), corresponding to a risk reduction of about
81 % for sudden cardiac death [10]. The changes in both
OS and OI observed in our study were similar and gave
comparable information on the LC n-3 PUFA status as
those reported previously [13]. However, our study was the
first to report subject dependent differential effect of LC
n-3 PUFA treatment. Here we identified weak responders
where the mean increase in OS was considerably, and
significantly less (50 %) than the mean increase of 132 %
that was observed with the combined group (n = 56).
Nevertheless, such an increase in OS still reduced the risk
for sudden death by 45 % as described previously [10]. The
majority of these subjects belonged to the hypertriglyceri-
demic group with an average BMI of 35.5 (obese). We also
observed strong responders who showed significantly
greater changes in OS with resulting endpoint OS levels of
[10.2 %. These subjects belonged to the normal to mar-
ginally high TG group with a significantly lower average
BMI of 27.5 (overweight), compared to the weak
responders. The majority of the subjects (59 %) were
average responders with a 121 % increase in OS levels and
73 % of these belonged to the Cohort 1. The numbers of
subjects on medication were similar among Cohorts (50 %
Cohort 1 and 45 % Cohort 2), although both weak and
strong responders had different drug regiments. Further
studies are needed to substantiate this novel finding and to
investigate the mechanism associated with these differen-
tial responses, as the sample size of the current study was
relatively small and the duration of the treatment was short.
However, it appears that the individual personal health,
particularly baseline TG levels, BMI, and the concomitant
use of drugs may play a role in the differential absorption
and metabolism of fish oils.
The Western Diet is abundant in n-6 fatty acids, and is
relatively low in n-3 PUFA, resulting in an overall pro-
inflammatory status mediated by AA versus EPA driven
processes that have direct effects on the vascular endo-
thelium, platelets, and immune cells [41, 42]. Although the
baseline AA:EPA ratio in relation to CVD has been
described previously, very few studies have shown pre- and
post-treatment changes. Here we report a substantial
decrease in the n-6:n-3 and AA:EPA ratios (51 % and
82 %, respectively), upon 8 weeks of treatment. These
decreases are less but comparable (54 % and 99 %,
respectively), to those observed recently with an EPA-only
formulation in patients with higher TG levels
([5.65 mmol/L) and for a longer (12 weeks as compared
to 8 weeks) treatment period [43]. Since inflammation
plays a significant role in the pathogenesis of CVD [44],
and the presence of a low AA:EPA ratio has been described
to prevent the onset or progression of CVD [45], significant
decreases in both AA:EPA and n-6:n-3 in the present study
are indicative of an improvement in the inflammatory
status of the subjects. Further studies elucidating the
downstream consequences of these low ratios are currently
being undertaken.
With respect to secondary endpoint measures, the data
presented here differ considerably from those reported in
other RCTs that utilized LC n-3 PUFA formulations with
similar purity ([90 %) and dose (4 g/day), but different
EPA:DHA ratios (1.2:1 & EPA-only), study duration, and
patient selection. In the present study, subjects with base-
line TG levels between 2.26 and 5.65 mmol/L, had a
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significant decrease in TG (48 %), and VLDL-C (30 %),
after 8 weeks of treatment. Placebo-corrected post-treat-
ment HDL-C levels improved a little and LDL-C levels did
not significantly change. In a comparable study of patients
with high TG levels (2.26–5.65 mmol/L), treatment with
an EPA-only formulation resulted in a less efficacious
reduction in TG (21 %), and VLDL-C (24 %), over a
longer treatment period [46] than the present study.
Treatment of patients with [500 mg/dL baseline TG level
with the same EPA-only formulation, resulted in a greater
decrease in TG (33 %) and VLDL (29 %) than that was
observed previously [26]; however, the reduction was still
less pronounced than reported here and over a shorter
period of treatment. No significant changes in HDL-C and
LDL-C levels were observed in those studies, while in our
study, only placebo-corrected improvement (9 %) in HDL-
C was observed. When an EPA:DHA formulation of 1.2:1
was utilized in another study of patients with[5.65 mmol/L
TG, a greater TG (52 %) and VLDL-C (41 %) reduction
was observed after 16 weeks of treatment, but with a sig-
nificant increase of up to 49 % in LDL-C [47, 48]. The
differences in the secondary endpoint parameters in the
above studies could be attributed to the differential prop-
erties of EPA and DHA [49], and the utilization of different
LC n-3 PUFA formulations with variable ratios. Both EPA
and DHA are known to reduce TG levels. However, DHA
alone can contribute to an increase in LDL-C levels, and
EPA alone is less efficacious at lowering TG and VLDL
levels as was observed in the above studies that investi-
gated patients with an EPA:DHA ratio of 1.2:1, or EPA-
alone formulations. The differences in the present study
could be attributed to the use of an optimal EPA:DHA
ratio. This 6:1-OM3 formulation has been shown to pro-
duce maximum and sustained vasodilatory effects in iso-
lated perfused porcine coronary artery rings than some
other known LC n-3 PUFA preparations [31]. Taken
together, on equivalent dose, purity, and patient selection
(equivalent baseline TG levels), a 6:1-OM3 formulation
shows the greatest TG, and VLDL-C reduction, without
significant increase in LDL-C levels, and in a shorter
treatment period.
The effects of LC n-3 PUFA supplementation on normal
to marginally high TG subjects (1.02–2.25 mmol/L) con-
siderably differ from their effects on subjects with high TG
(2.26–5.65 mmol/L), or very high TG ([ 5.65 mmol/L).
To our knowledge, little is known about the impact of LC
n-3 PUFA in subjects with normal to marginally high TG.
Although comparable RCT data in such group is not
available, the present study shows a downward, but non-
significant effect on TG and VLDL-C levels upon treat-
ment, without affecting other lipids. However, the correc-
tion of LC n-3 PUFA deficiency, as measured by OS
showed a similar increase of 132 %, with significant and
equal reduction in the n-6:n-3 and AA:EPA ratios
(-48.6 % and -93 %, respectively) when compared with
hypertriglyceridemic subjects. This suggests that beneficial
effects of LC n-3 PUFA are more than simply reduction in
serum TG levels. Other secondary endpoints such as apo-
A, apo-B, hs-CRP, BMI, and blood pressure, did not reach
statistical significance, irrespective of the Cohorts and may
require longer treatment regiment to claim differences.
From the above discussion, it is apparent that the efficacy
of LC n-3 PUFA treatment of hypertriglyceridemia appears
to be dependent upon the severity of dyslipidemia; the
higher the baseline TG level, the greater the potential per-
cent reduction upon treatment. Also, the efficacy of a for-
mulation to improve lipid profiles, inflammatory indices,
and vasodilatory effects appear to be EPA:DHA ratio
dependent. To this end, higher circulating DHA levels have
been shown to be associated with lower incidence of atrial
fibrillation and play an important role in the protection from
sudden death from cardiac causes [12, 50]. Whether related
or not, protection from sudden death was observed in the
landmark GISSI study, that utilized a formulation contain-
ing DHA in contrast to the JELIS study that utilized an
EPA-alone formulation, where this protection was not
observed, [18, 19]. The greatest protection from cardio-
vascular mortality including coronary heart disease,
arrhythmic, and non-arrhythmic mortality has been descri-
bed to be associated with the highest plasma phospholipid
DHA levels, while non-fatal myocardial infarction mortal-
ity was associated with the highest plasma phospholipid
EPA levels [12]. Thus, it appears that inclusion of low
amounts of DHA with EPA in LC n-3 PUFA formulations
offers the greatest potential for correction of LC n-3 PUFA
deficiency-associated CVD risks, without increasing LDL-
C. In addition, increased levels of DPA have been associ-
ated with lower risk (47 %) for stroke death and may,
together with EPA, contribute to plaque stability [51].
The data presented here show that a 6:1 EPA:DHA ratio
appears to be optimal for correcting LC n-3 PUFA nutri-
tional deficiency, with concomitant positive effects on lipid
profiles and on inflammatory indices. As mentioned by
others [27, 28], the present study also highlights the need to
consider LC n-3 PUFA dose and EPA:DHA ratio in the
treatment formulation, patient selection, as well as the
importance of pre- and post-treatment measurement of OS
and/or OI. Further studies with lager patient enrollment and
of longer treatment duration are needed to investigate
beneficial, and differential effects of LC n-3 PUFA intake
on heath, inflammation, and mortality due to CVD.
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